Cargando…

SARS‐CoV‐2 and pregnancy outcomes under universal and non‐universal testing in Sweden: register‐based nationwide cohort study

OBJECTIVE: To assess associations of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and pregnancy outcomes considering testing policy and test‐positivity‐to‐delivery interval. DESIGN: Nationwide cohort study. SETTING: Sweden. POPULATION: From the Pregnancy‐Register we identif...

Descripción completa

Detalles Bibliográficos
Autores principales: Stephansson, O, Pasternak, B, Ahlberg, M, Hervius Askling, H, Aronsson, B, Appelqvist, E, Jonsson, J, Sengpiel, V, Söderling, J, Norman, M, Ludvigsson, JF, Neovius, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652549/
https://www.ncbi.nlm.nih.gov/pubmed/34706148
http://dx.doi.org/10.1111/1471-0528.16990
_version_ 1784611597183877120
author Stephansson, O
Pasternak, B
Ahlberg, M
Hervius Askling, H
Aronsson, B
Appelqvist, E
Jonsson, J
Sengpiel, V
Söderling, J
Norman, M
Ludvigsson, JF
Neovius, M
author_facet Stephansson, O
Pasternak, B
Ahlberg, M
Hervius Askling, H
Aronsson, B
Appelqvist, E
Jonsson, J
Sengpiel, V
Söderling, J
Norman, M
Ludvigsson, JF
Neovius, M
author_sort Stephansson, O
collection PubMed
description OBJECTIVE: To assess associations of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and pregnancy outcomes considering testing policy and test‐positivity‐to‐delivery interval. DESIGN: Nationwide cohort study. SETTING: Sweden. POPULATION: From the Pregnancy‐Register we identified 88 593 singleton births, 11 March 2020–31 January 2021, linked to data on SARS‐CoV‐2‐positivity from the Public Health Agency, and information on neonatal care admission from the Neonatal Quality Register. Adjusted odds ratios (aORs) were estimated stratified by testing‐policy and test‐positivity‐to‐delivery interval. MAIN OUTCOME MEASURES: Five‐minute Apgar score, neonatal care admission, stillbirth and preterm birth. RESULTS: During pregnancy, SARS‐CoV‐2 test‐positivity was 5.4% (794/14 665) under universal testing and 1.9% (1402/73 928) under non‐universal testing. There were generally lower risks associated with SARS‐CoV‐2 under universal than non‐universal testing. In women testing positive >10 days from delivery, generally no significant differences in risk were observed under either testing policy. Neonatal care admission was more common (15.3% versus 8.0%; aOR 2.24, 95% CI 1.62–3.11) in women testing positive ≤10 days before delivery under universal testing. There was no significant association with 5‐minute Apgar score below 7 (1.0% versus 1.7%; aOR 0.64, 95% CI 0.24–1.72) or stillbirth (0.3% versus 0.4%; aOR 0.72, 95% CI 0.10–5.20). Compared with term births (2.1%), test‐positivity was higher in medically indicated preterm birth (5.7%; aOR 2.70, 95% CI 1.60–4.58) but not significantly increased in spontaneous preterm birth (2.3%; aOR 1.12, 95% CI 0.62–2.02). CONCLUSIONS: Testing policy and timing of test‐positivity impact associations between SARS‐CoV‐2‐positivity and pregnancy outcomes. Under non‐universal testing, women with complications near delivery are more likely to be tested than women without complications, thereby inflating any association with adverse pregnancy outcomes compared with findings under universal testing. TWEETABLE ABSTRACT: Testing policy and time from SARS‐CoV‐2 infection to delivery influence the association with pregnancy outcomes.
format Online
Article
Text
id pubmed-8652549
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-86525492021-12-08 SARS‐CoV‐2 and pregnancy outcomes under universal and non‐universal testing in Sweden: register‐based nationwide cohort study Stephansson, O Pasternak, B Ahlberg, M Hervius Askling, H Aronsson, B Appelqvist, E Jonsson, J Sengpiel, V Söderling, J Norman, M Ludvigsson, JF Neovius, M BJOG Research Articles OBJECTIVE: To assess associations of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and pregnancy outcomes considering testing policy and test‐positivity‐to‐delivery interval. DESIGN: Nationwide cohort study. SETTING: Sweden. POPULATION: From the Pregnancy‐Register we identified 88 593 singleton births, 11 March 2020–31 January 2021, linked to data on SARS‐CoV‐2‐positivity from the Public Health Agency, and information on neonatal care admission from the Neonatal Quality Register. Adjusted odds ratios (aORs) were estimated stratified by testing‐policy and test‐positivity‐to‐delivery interval. MAIN OUTCOME MEASURES: Five‐minute Apgar score, neonatal care admission, stillbirth and preterm birth. RESULTS: During pregnancy, SARS‐CoV‐2 test‐positivity was 5.4% (794/14 665) under universal testing and 1.9% (1402/73 928) under non‐universal testing. There were generally lower risks associated with SARS‐CoV‐2 under universal than non‐universal testing. In women testing positive >10 days from delivery, generally no significant differences in risk were observed under either testing policy. Neonatal care admission was more common (15.3% versus 8.0%; aOR 2.24, 95% CI 1.62–3.11) in women testing positive ≤10 days before delivery under universal testing. There was no significant association with 5‐minute Apgar score below 7 (1.0% versus 1.7%; aOR 0.64, 95% CI 0.24–1.72) or stillbirth (0.3% versus 0.4%; aOR 0.72, 95% CI 0.10–5.20). Compared with term births (2.1%), test‐positivity was higher in medically indicated preterm birth (5.7%; aOR 2.70, 95% CI 1.60–4.58) but not significantly increased in spontaneous preterm birth (2.3%; aOR 1.12, 95% CI 0.62–2.02). CONCLUSIONS: Testing policy and timing of test‐positivity impact associations between SARS‐CoV‐2‐positivity and pregnancy outcomes. Under non‐universal testing, women with complications near delivery are more likely to be tested than women without complications, thereby inflating any association with adverse pregnancy outcomes compared with findings under universal testing. TWEETABLE ABSTRACT: Testing policy and time from SARS‐CoV‐2 infection to delivery influence the association with pregnancy outcomes. John Wiley and Sons Inc. 2021-11-18 2022-01 /pmc/articles/PMC8652549/ /pubmed/34706148 http://dx.doi.org/10.1111/1471-0528.16990 Text en © 2021 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Stephansson, O
Pasternak, B
Ahlberg, M
Hervius Askling, H
Aronsson, B
Appelqvist, E
Jonsson, J
Sengpiel, V
Söderling, J
Norman, M
Ludvigsson, JF
Neovius, M
SARS‐CoV‐2 and pregnancy outcomes under universal and non‐universal testing in Sweden: register‐based nationwide cohort study
title SARS‐CoV‐2 and pregnancy outcomes under universal and non‐universal testing in Sweden: register‐based nationwide cohort study
title_full SARS‐CoV‐2 and pregnancy outcomes under universal and non‐universal testing in Sweden: register‐based nationwide cohort study
title_fullStr SARS‐CoV‐2 and pregnancy outcomes under universal and non‐universal testing in Sweden: register‐based nationwide cohort study
title_full_unstemmed SARS‐CoV‐2 and pregnancy outcomes under universal and non‐universal testing in Sweden: register‐based nationwide cohort study
title_short SARS‐CoV‐2 and pregnancy outcomes under universal and non‐universal testing in Sweden: register‐based nationwide cohort study
title_sort sars‐cov‐2 and pregnancy outcomes under universal and non‐universal testing in sweden: register‐based nationwide cohort study
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652549/
https://www.ncbi.nlm.nih.gov/pubmed/34706148
http://dx.doi.org/10.1111/1471-0528.16990
work_keys_str_mv AT stephanssono sarscov2andpregnancyoutcomesunderuniversalandnonuniversaltestinginswedenregisterbasednationwidecohortstudy
AT pasternakb sarscov2andpregnancyoutcomesunderuniversalandnonuniversaltestinginswedenregisterbasednationwidecohortstudy
AT ahlbergm sarscov2andpregnancyoutcomesunderuniversalandnonuniversaltestinginswedenregisterbasednationwidecohortstudy
AT herviusasklingh sarscov2andpregnancyoutcomesunderuniversalandnonuniversaltestinginswedenregisterbasednationwidecohortstudy
AT aronssonb sarscov2andpregnancyoutcomesunderuniversalandnonuniversaltestinginswedenregisterbasednationwidecohortstudy
AT appelqviste sarscov2andpregnancyoutcomesunderuniversalandnonuniversaltestinginswedenregisterbasednationwidecohortstudy
AT jonssonj sarscov2andpregnancyoutcomesunderuniversalandnonuniversaltestinginswedenregisterbasednationwidecohortstudy
AT sengpielv sarscov2andpregnancyoutcomesunderuniversalandnonuniversaltestinginswedenregisterbasednationwidecohortstudy
AT soderlingj sarscov2andpregnancyoutcomesunderuniversalandnonuniversaltestinginswedenregisterbasednationwidecohortstudy
AT normanm sarscov2andpregnancyoutcomesunderuniversalandnonuniversaltestinginswedenregisterbasednationwidecohortstudy
AT ludvigssonjf sarscov2andpregnancyoutcomesunderuniversalandnonuniversaltestinginswedenregisterbasednationwidecohortstudy
AT neoviusm sarscov2andpregnancyoutcomesunderuniversalandnonuniversaltestinginswedenregisterbasednationwidecohortstudy